ArticleFrontiers in oncology2024
Unveiling the role of ASPP1 in cancer progression: pan-cancer bioinformatics and experimental validation in colorectal cancer.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- C17orf75 (Njmu-R1) promotes hepatocellular carcinoma progression: a pan-cancer analysis and experimental validation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Apoptosis-Stimulating Protein of P53 (ASPP) family contributes to apoptosis regulation and tumor suppression, with ASPP1 influencing processes like cancer cell proliferation, invasion, and migration. Its expression varies across cancer types, suggesting a potential role in oncogenesis. Methods: This study investigates ASPP1's role across various cancers using a comprehensive bioinformatics approach. Data were extracted from public resources, including The Cancer Genome Atlas (TCGA), GTEx, and the Human Protein Atlas, and analyzed via tools such as cBioPortal, GEPIA, and TIMER2. Statistical and network analyses were performed with R, Cytoscape, and Hiplot. ASPP1's function in colorectal cancer was further explored through Results: ASPP1 expression exhibited significant variability across different cancer types, with marked associations with patient outcomes, particularly overall survival (OS) and disease-specific survival (DSS) across several cancer types. In-depth protein-protein interaction (PPI) analysis revealed ASPP1's involvement in apoptosis and cancer progression networks. Functional enrichment analysis further linked ASPP1 to key apoptotic signaling pathways and transcriptional regulatory processes, underscoring its potential impact on tumor biology. Additionally, the expression of ASPP1 correlates with immune cell infiltration patterns, including cancer-associated fibroblasts and various immune markers, suggesting roles in immune response modulation. Conclusion: This study highlights ASPP1 as a forecasting biomarker in the colorectal cancers and potentially across other cancers. The findings support ASPP1's involvement in tumor biology, particularly regarding cell proliferation and metastatic potential, establishing a foundation for further investigation into its therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.